Literature DB >> 118811

Costs and benefits of measles and mumps immunization in Austria.

G Wiedermann, F Ambrosch.   

Abstract

The usefulness of an immunization programme can be evaluated by comparing either risks and benefits or costs and benefits. By means of special formulae, the benefit-cost ratio and the benefit-cost difference can be calculated for monovalent and bivalent vaccines. An analysis of combined measles-mumps immunization in Austria showed that this measure is highly profitable economically. Since employed mothers are allowed one week's vacation each year to nurse a sick child, this affects the calculations. Including the cost of the "nursing vacation" among the benefits that would be realized following an immunization programme, the estimated benefit-cost ratio is 4.48; if the cost of the "nursing vacation" is omitted the ratio is 2.65. The estimated annual benefit-cost differences are AS 1681.90 and AS 672.85, respectively, per child. Twelve years after the beginning of a programme to immunize 100 000 1-year-old children per year (corresponding roughly to the birth rate in Austria) an amount of AS 528 million would be saved if the "nursing vacation" is included in the calculations and an amount of AS 63 million if it is not.

Entities:  

Mesh:

Year:  1979        PMID: 118811      PMCID: PMC2395836     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  10 in total

1.  [Epidemiological investigations on measles in unvaccinated and vaccinated children (author's transl)].

Authors:  G Wiedermann; F Ambrosch
Journal:  Wien Klin Wochenschr       Date:  1976-09-17       Impact factor: 1.704

Review 2.  [Problems of vaccination].

Authors:  G Wiedermann; F Ambrosch
Journal:  Wien Med Wochenschr       Date:  1974-03-16

3.  Live, attenuated mumps-virus vaccine.

Authors:  M R Hilleman; E B Buynak; R E Weibel; J Stokes
Journal:  N Engl J Med       Date:  1968-02-01       Impact factor: 91.245

4.  [Cost-benefit analysis in measles and mumps vaccinations].

Authors:  G Wiedermann; F Ambrosch
Journal:  Wien Med Wochenschr       Date:  1978-02-15

5.  Infants' responses to live, attenuated, B level, Jeryl Lynn mumps vaccine.

Authors:  J Wilkins; F F Williams; P F Wehrle
Journal:  Am J Dis Child       Date:  1972-07

6.  Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study.

Authors:  J D Cherry; R D Feigin; L A Lobes; D R Hinthorn; P G Shackelford; R H Shirley; R D Lins; S C Choi
Journal:  J Pediatr       Date:  1972-08       Impact factor: 4.406

7.  Simple method for rough determination of the cost-benefit balance point of immunization programmes.

Authors:  B Grab; B Cvjetanovic
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

8.  Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation.

Authors:  M R Hilleman; R E Weibel; E B Buynak; J Stokes; J E Whitman
Journal:  N Engl J Med       Date:  1967-02-02       Impact factor: 91.245

9.  [Mathematical methods to judge the efficiency of protective vaccinations (author's transl)].

Authors:  F Ambrosch; G Wiedermann
Journal:  Immun Infekt       Date:  1975-02

10.  [Costs and benefits of measles vaccination].

Authors:  F Ambrosch; G Wiedermann; G Harasek
Journal:  Fortschr Med       Date:  1978-02-23
  10 in total
  4 in total

1.  Close the gap for routine mumps vaccination in Japan.

Authors:  Taito Kitano
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452

2.  Why we need to continue to immunize against mumps.

Authors:  R Gugelmann
Journal:  Soz Praventivmed       Date:  1995

3.  Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital.

Authors:  Taito Kitano; Masayuki Onaka; Mariko Ishihara; Atsuko Nishiyama; Naoki Hashimoto; Sayaka Yoshida
Journal:  Clin Exp Vaccine Res       Date:  2017-07-26

4.  Dynamic transmission model of routine mumps vaccination in Japan.

Authors:  Taito Kitano
Journal:  Epidemiol Infect       Date:  2018-12-03       Impact factor: 2.451

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.